卫光生物(002880) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥278,265,022.30, representing a 54.95% increase year-over-year[5] - Net profit attributable to shareholders was ¥50,215,465.97, up 94.01% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥48,268,848.87, reflecting a 97.76% increase year-over-year[5] - The company reported a significant increase in cash flow from operating activities, with a net amount of ¥215,850,869.32, up 451.56% year-to-date[5] - The company reported a total comprehensive income of CNY 151,348,408.60, compared to CNY 72,732,672.12 in the previous period, highlighting improved financial performance[16] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,665,468,277.92, a 3.48% increase from the end of the previous year[5] - Total assets as of September 30, 2023, amounted to CNY 2,665,468,277.92, an increase from CNY 2,575,733,822.26 at the beginning of the year[12] - Current assets decreased to CNY 1,078,659,822.13 from CNY 1,133,123,579.22, primarily due to a reduction in cash and accounts receivable[12] - Total liabilities decreased to CNY 691,946,321.50 from CNY 708,199,697.29, reflecting a reduction in current liabilities[13] - Non-current assets increased to CNY 1,586,808,455.79 from CNY 1,442,610,243.04, driven by growth in fixed assets[13] Shareholder Information - The company has no preferred shareholders as of the reporting date[11] - The top shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares, totaling 147,987,000 shares[10] Earnings and Profitability - The company's basic earnings per share rose to ¥0.2214, a 94.05% increase from the same period last year[5] - Operating profit for the period was CNY 178,634,888, up 110.7% from CNY 84,576,313 in the previous period[16] - Net profit attributable to shareholders of the parent company was CNY 151,241,017, representing a 107.5% increase from CNY 72,769,914 in the previous period[16] - Basic and diluted earnings per share increased to CNY 0.6668, compared to CNY 0.3209 in the previous period[17] Research and Development - Research and development expenses for the period were ¥50,435,388.95, an increase of 78.37% compared to the previous year[8] - Research and development expenses increased to CNY 50,435,388.95, up from CNY 28,275,340.82 in the previous period, indicating a focus on innovation[15] Cash Flow - The net cash flow from investment activities was -225,060,828.76 CNY, compared to -181,594,782.57 CNY in the previous period, indicating an increase in cash outflow[18] - The cash inflow from financing activities totaled 123,391,065.12 CNY, down from 424,793,884.69 CNY in the previous period[18] - The net cash flow from financing activities was -93,042,457.83 CNY, a significant decrease from 394,389,158.72 CNY in the previous period[18] - The total cash and cash equivalents at the end of the period were 192,239,644.28 CNY, down from 483,500,609.89 CNY at the end of the previous period[18] - The company reported a net decrease in cash and cash equivalents of -102,252,417.27 CNY for the quarter[18] Inventory and Accounts Receivable - Inventory increased to CNY 687,633,973.81, up from CNY 605,510,451.16, indicating a 13.5% rise[12] - Accounts receivable decreased to CNY 64,776,677.66 from CNY 102,844,379.69, a reduction of about 37%[12] Audit Information - The company did not undergo an audit for the third quarter report[19]